Four months af­ter first in­tranasal flunks in­fluen­za test, Rev­e­la­tion's sec­ond-gen as­set miss­es on ef­fi­ca­cy

Rev­e­la­tion Bio­sciences had big plans for 2022 af­ter go­ing pub­lic via a SPAC in Jan­u­ary and al­so rais­ing $7.7 mil­lion in PIPE fi­nanc­ing lat­er that month, but two tri­al flops have hit the small cap biotech in re­cent months.

The com­pa­ny’s first-gen­er­a­tion in­tranasal drug missed the mark on a Phase IIb study in in­fluen­za in March, and af­ter the clos­ing bell on Fri­day, the San Diego biotech said its sec­ond-gen in­tranasal ther­a­py was safe and tol­er­a­ble in a Phase Ib study, but there was no sign of ef­fi­ca­cy in re­duc­ing al­ler­gy symp­toms and in­creas­ing air­flow through the nose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER